Herpes Simplex Virus Type 2 and Risk of Intrapartum Human Immunodeficiency Virus Transmission
Overview
Authors
Affiliations
Objective: To determine whether herpes simplex virus type 2 (HSV-2) infection was associated with risk of intrapartum human immunodeficiency virus type 1 (HIV-1) transmission and to define correlates of HSV-2 infection among HIV-1-seropositive pregnant women.
Methods: We performed a nested case control study within a perinatal cohort in Nairobi, Kenya. Herpes simplex virus type 2 serostatus and the presence of genital ulcers were ascertained at 32 weeks of gestation. Maternal cervical and plasma HIV-1 RNA and cervical HSV DNA were measured at delivery.
Results: One hundred fifty-two (87%) of 175 HIV-1-infected mothers were HSV-2-seropositive. Among the 152 HSV-2-seropositive women, nine (6%) had genital ulcers at 32 weeks of gestation, and 13 (9%) were shedding HSV in cervical secretions. Genital ulcers were associated with increased plasma HIV-1 RNA levels (P=.02) and an increased risk of intrapartum HIV-1 transmission (16% of transmitters versus 3% of nontransmitters had ulcers; P = .003), an association which was maintained in multivariable analysis adjusting for plasma HIV-1 RNA levels (P=.04). We found a borderline association for higher plasma HIV-1 RNA among women shedding HSV (P=.07) and no association between cervical HSV shedding and either cervical HIV-1 RNA levels or intrapartum HIV-1 transmission (P=.4 and P=.5, [corrected] respectively).
Conclusion: Herpes simplex virus type 2 is the leading cause of genital ulcers among women in sub-Saharan Africa and was highly prevalent in this cohort of pregnant women receiving prophylactic zidovudine. After adjusting for plasma HIV-1 RNA levels, genital ulcers were associated with increased risk of intrapartum HIV-1 transmission. These data suggest that management of HSV-2 during pregnancy may enhance mother-to-child HIV-1 prevention efforts.
Level Of Evidence: II.
Owen E, Jama M, Nahal B, Clarke E, Obasi A BMJ Glob Health. 2024; 9(7).
PMID: 38964882 PMC: 11227757. DOI: 10.1136/bmjgh-2024-015167.
Understanding Viral and Immune Interplay During Vertical Transmission of HIV: Implications for Cure.
Amin O, Powers J, Bricker K, Chahroudi A Front Immunol. 2021; 12:757400.
PMID: 34745130 PMC: 8566974. DOI: 10.3389/fimmu.2021.757400.
Roxby A, Yuhas K, Farquhar C, Bosire R, Mbori-Ngacha D, Richardson B AIDS. 2019; 33(14):2211-2217.
PMID: 31385863 PMC: 6832839. DOI: 10.1097/QAD.0000000000002335.
Ellington S, King C, Kourtis A Future Virol. 2018; 6(2):1451-1469.
PMID: 29348780 PMC: 5769959. DOI: 10.2217/fvl.11.119.
Adachi K, Xu J, Yeganeh N, Camarca M, Morgado M, Watts D PLoS One. 2018; 13(1):e0189851.
PMID: 29304083 PMC: 5755782. DOI: 10.1371/journal.pone.0189851.